Kyle Amber to Pneumonia, Pneumocystis
This is a "connection" page, showing publications Kyle Amber has written about Pneumonia, Pneumocystis.
Connection Strength
4.222
-
Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.
Score: 0.781
-
The risk of Pneumocystis pneumonia in patients of?autoimmune blistering disease-reply to letter entitled "Pemphigus management guidelines: A life-saving perspective". J Am Acad Dermatol. 2021 11; 85(5):e289.
Score: 0.745
-
Disease-dependent Risk of Pneumocystis Pneumonia: The Case of Autoimmune Blistering Disease. Chest. 2020 12; 158(6):2704-2705.
Score: 0.714
-
Dapsone, 2 birds with 1 stone: A response to "Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients". J Am Acad Dermatol. 2021 12; 85(6):e369.
Score: 0.638
-
Comment on "Incidence of pneumocystosis among patients exposed to immunosuppression". J Am Acad Dermatol. 2019 08; 81(2):e47.
Score: 0.635
-
Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatol. 2017 11 01; 153(11):1137-1141.
Score: 0.576
-
Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions". Int J Dermatol. 2017 01; 56(1):e4-e5.
Score: 0.133